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Objectives We sought to examine the characteristics, quality of care, and clinical outcomes for a large cohort of African-
American patients hospitalized with heart failure (HF) in centers participating in a quality improvement initiative.
Background Heart failure in African Americans is characterized by variations in natural history, lesser response to evidence-
based therapies, and disparate health care. We hypothesized that a performance improvement program will
achieve similar adherence to quality measures in African Americans admitted with HF compared with
non–African Americans.
Methods The OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Fail-
ure) registry-based performance-improvement program includes a pre-specified 10% subgroup with 60- to 90-
day follow-up. Data on quality of care measures and outcomes were analyzed for 8,608 African-American pa-
tients compared with 38,501 non–African-American patients.
Results African Americans were significantly younger and more likely to receive evidence-based medications but less
likely to receive discharge instructions and smoking cessation counseling. In multivariable analyses, African-
American race was an independent predictor of lower in-hospital mortality (odds ratio 0.71; 95% confidence
interval 0.57 to 0.87; p  0.001) but similar hospital length of stay. After multivariable adjustment, post-
discharge outcomes were similar for American-American and non–African-American patients, but African-
American race was associated with higher angiotensin-converting enzyme inhibitor prescription and left ventricu-
lar function assessment; no other HF quality indicators were influenced by race.
Conclusions In the context of a performance-improvement program, African Americans with HF received similar or better
treatment with evidence-based medications, less discharge counseling, had better in-hospital survival, and simi-
lar adjusted risk of follow-up death/repeat hospital stay. (Organized Program to Initiate Lifesaving Treatment In
Hospitalized Patients With Heart Failure [OPTIMIZE-HF]; NCT00344513) (J Am Coll Cardiol 2008;51:1675–84)
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African Americans Hospitalized With HF: The OPTIMIZE-HF Registry April 29, 2008:1675–84Marked population differences
exist in the prevalence, morbid-
ity, and mortality associated with
cardiovascular disease. In con-
junction with biological risk fac-
tors, social and environmental
determinants of cardiovascular
disease might contribute to the
treatment and outcome inequi-
ties seen in different populations
(1). These differences have the
potential to contribute to ob-
served gaps in the overall life
expectancy and quality of life and
are felt to be partly responsible
for health care disparities. Afri-
can Americans are among those
most seriously affected by dispar-
ate health care in the U.S. (2).
Recent statistics confirm that
ardiovascular disease is the leading cause of death for
frican Americans (3,4). Heart failure (HF) is especially
roblematic for African Americans. Both the prevalence of
F and mortality due to chronic HF are increased in
frican Americans compared with the general population
4,5). The etiology of left ventricular dysfunction leading to
F in African Americans is also different, and the natural
istory is more aggressive than that seen in other popula-
ions. Among African-American patients with HF and left
entricular systolic dysfunction (LVSD), only one-fourth of
atients have a known ischemic etiology of LVSD, with the
emainder experiencing a putative nonischemic etiology of
VSD (6). In addition, HF occurs at an earlier age in
frican-American patients, with more advanced LVSD and
orse clinical class at the time of diagnosis than seen in the
opulation at large (7).
Despite being at high risk for cardiovascular morbidity
nd mortality, prior studies have indicated that African
mericans are less likely than non-African Americans to
eceive guideline-recommended, evidence-based care such
s diagnostic testing, drug therapy, and interventional pro-
edures (8–10). The reasons for these disparities in health
are are multifactorial, however, and might be related to
ccess to care, patient preference, or bias (11). Recent
tudies also document that African-American patients are
ore likely to be treated at hospitals that provide poor
uality of care with lower use of systematic processes,
rotocols, and evidence-based treatments (12–14). More-
ver, even when treated at the same hospital, African-
merican patients might not receive the same standard of
are delivered to white patients (12,15).
The quality of care for African Americans admitted with
F has not been well studied in the context of an HF
uality improvement program. The OPTIMIZE-HF (Or-
anized Program to Initiate Lifesaving Treatment in Hos-
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
BNP  B-type natriuretic
peptide
CI  confidence interval
HF  heart failure
LVEF  left ventricular
ejection fraction
LVSD  left ventricular
systolic dysfunction
OR  odds ratioitalized Patients with Heart Failure) registry provides an epportunity to capture quality indicators as a function of
ace and investigate their association with outcomes. The
PTIMIZE-HF program is designed to improve medical
are and education for hospitalized HF patients and to
ccelerate use of evidence-based, guideline-recommended
herapies by initiating them before hospital discharge.
hese process-of-care intervention strategies might stan-
ardize care for all patients with HF and test whether
frican Americans with HF who are treated similarly will
xperience the same outcomes as other HF populations
16). Our analyses investigated the influence of this quality-
mprovement initiative in a large African-American subgroup
nd the association with quality of care, post-discharge HF
anagement, survival, and repeat hospital stay.
ethods
tudy design. The study design and rationale of the
PTIMIZE-HF registry has been previously published
17–20). Briefly, OPTIMIZE-HF is a registry and
erformance-improvement program for patients hospital-
zed with HF. This nationwide patient registry was used to
ather data on various patient characteristics with a web-
ased information system. Participating hospitals had the
bility to view national aggregate hospital data as well as
aily patient and performance data benchmarked with
imilar hospitals. The OPTIMIZE-HF process-of-care
mprovement program provided participating hospitals with
aterials for improving treatment and discharge plans for
ptimal patient management and included evidence-based
est-practice algorithms (detailed algorithms on indications,
ontraindications, dosing, and monitoring steps for each
vidence-based HF therapy) along with comprehensive
atient education materials and resources. To be eligible for
PTIMIZE-HF, patients had to be adults hospitalized for
n episode of HF as the primary cause of admission or with
ignificant HF symptoms that developed during hospital
tay with a primary discharge diagnosis of HF. With
ethodology similar to national cardiovascular registries
nd many randomized trials, race and ethnicity were col-
ected for the purpose of evaluating subgroup differences.
dmission and/or medical staff recorded race/ethnicity,
sually as the patient was registered. Patients were assigned
o race and ethnicity categories with options defined by the
tudy protocol. A pre-specified subgroup (10%) had 60- to
0-day follow-up data collected. Participating sites had the
ption of participating in the hospital registry only or
ospital registry and follow-up data collection. Site partic-
pation in the follow-up portion required obtaining in-
ormed consent. This follow-up cohort was demographi-
ally similar to patients in the overall registry (Online Table
). Process-of-care improvement tool use was defined by use
f either preprinted order sets or discharge checklists as
ocumented in the medical record. Left ventricular systolic
ysfunction was defined as a documented left ventricular
jection fraction (LVEF)40% or qualitative assessment of
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April 29, 2008:1675–84 African Americans Hospitalized With HF: The OPTIMIZE-HF Registryoderate/severe dysfunction. The registry coordinating
enter was Outcome Sciences, Inc. (Cambridge, Massachu-
etts), which provided data collection, management, and
ource data verification.
tatistical analyses. Discrete data are reported as the
umber and frequency of eligible patients treated at the time
f hospital discharge, excluding patients with documented
ntolerance/contraindications to specific therapies. The HF
edication use and contraindications/intolerance were as-
essed at discharge from the index hospital stay and during
ollow-up. Race was analyzed according to African-
merican and non–African-American status. Patient char-
cteristics and evidence-based treatments at hospital dis-
harge were compared with the Pearson chi-square test for
ategorical variables and analysis of variance for continuous
Patient Characteristics
Table 1 Patient Characteristics
Characteristic
Af
Age, mean  SD, yrs
Female, %
Hypertensive etiology, %
Ischemic etiology, %
Atrial arrhythmia, %
Patients with LVF assessed, n (%) 7,3
LVEF (in those measured), mean  SD, %
LVSD (LVEF 40% or moderate/severe LVD), %
Left heart catheterization, %
CABG, %
Dialysis, %
CAD/IHD, %
Hyperlipidemia, %
Insulin-treated diabetes, %
Non–insulin-treated diabetes, %
COPD, %
Depression, %
Cigarette smoker within past yr, %
Serum creatinine, mean  SD, mg/dl
Serum creatinine, mean  SD, mol/l
Serum creatinine 2 mg/dl, %
Hemoglobin, mean  SD, g/dl
Hemoglobin, mean  SD, g/l
Patients with BNP measured, n (%) 4,3
BNP, median (25th, 75th), pg/ml 9
Troponin I, median (25th, 75th), ng/ml
Troponin I, median (25th, 75th), g/l
Admission weight, mean  SD, kg
Weight change from admission, mean  SD, kg 
Admission SBP, mean  SD, mm Hg 1
Discharge SBP, mean  SD, mm Hg 1
Admission HR, mean  SD, beats/min
Discharge HR, mean SD, beats/min
Admission jugular venous pressure elevation, %
Admission rales, %
BNP B-type natriuretic peptide; CABG coronary artery bypass graft;
obstructive pulmonary disease; HR  heart rate; LVD  left ventricula
function; LVSD  left ventricular systolic dysfunction; SBP  systolic bariables. Models of in-hospital mortality, mortality from fospital discharge to 90 days, and the combination of
ost-discharge mortality or repeat hospital stay have been
eveloped to determine significant factors to use when
pplying adjusted models (Online Table 2) (19,20). Baseline
linical and treatment factors were applied to model selec-
ions. To model in-hospital mortality, 45 potential predictor
ariables were used in a logistic model. To model post-
ischarge mortality in the follow-up period, 19 potential
redictor variables were used in a Cox proportional hazards
odel. To model repeat hospital stay and the combination
f post-discharge mortality or repeat hospital stay, 69
ariables were used in a logistic model. To model confor-
ity with quality of care measures, 69 variables were
onsidered, and those retained for each model are listed in
nline Table 2. A p value of 0.05 was used as the criterion
merican
,608)
Non-African American
(n  38,581) p Value
 15.4 75.2 12.7 0.0001
.7 51.4 0.0287
.2 19.3 0.0001
.5 49.4 0.0001
.3 33.8 0.0001
.0) 32,648 (84.6) 0.002
 17.8 39.7 17.5 0.0001
.9 47.1 0.0001
.1 8.5 0.0001
.4 1.0 0.0001
.0 4.2 0.0001
.6 52.2 0.0001
.7 33.8 0.0001
.4 16.2 0.0001
.7 24.7 0.0345
.6 28.9 0.0001
.4 11.4 0.0001
.3 14.2 0.0001
 1.3 1.6 1.0 0.0001
 113.8 141.8 90.4 0.0001
.7 19.2 0.0001
 2.1 12.1 2.0 0.0001
 20.5 121.2 20.4 0.0001
.5) 26,086 (67.6) 0.0001
0, 2,130) 785 (403, 1,600) 0.0001
.1, 0.5) 0.1 (0.0, 0.3) 0.0001
1, 0.5) 0.1 (0.0, 0.3) 0.0001
 29.99 80.79 25.03 0.0001
 5.33 2.53 4.67 0.4332
 35.98 140.34 31.73 0.0001
 23.37 123.74 22.10 0.0001
 20.85 85.76 21.48 0.0001
 14.15 75.62 14.12 0.0001
.9 31.6 0.0001
.7 64.0 0.5493
D coronary artery disease/ischemic heart disease; COPD chronic
ction; LVEF  left ventricular ejection fraction; LVF  left ventricular
ressure.rican A
(n  8
63.6
52
39
29
16
99 (86
35.4
56
10
0
9
37
24
19
25
21
6
27
1.8
156.5
21
12.0
120.1
49 (50
65 (45
0.2 (0
0.2 (0.
90.67
2.59
53.06
29.27
90.27
77.73
36
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African Americans Hospitalized With HF: The OPTIMIZE-HF Registry April 29, 2008:1675–84inearity was checked in each model for the continuous
ariables by using restricted cubic splines. When the rela-
ionship was found to be nonlinear, appropriate transforma-
ions were applied. When the association between race and
epeat hospital stay was examined, all variables from the
ost-discharge death or repeat hospital stay model were
ncluded. Generalized estimating equations were used to
ccount for the correlation of data within the same hospital
n the adjusted models. The SAS version 8.2 (SAS Institute,
ary, North Carolina) was used for all statistical analyses,
hich were performed independently at Duke Clinical
esearch Institute (Durham, North Carolina).
esults
atient characteristics. The OPTIMIZE-HF registry en-
olled patients from March 1, 2003 through December 31,
004 and included 48,612 patients from 259 hospitals, with
re-specified follow-up data available from 91 centers and
,791 patients. Race was available for 47,190 (97.1%) patients.
f these, 8,608 (17.7%) were African Americans; follow-up
ata were collected from 1,044 African-American patients.
atient characteristics are detailed in Table 1. The charac-
eristics of African Americans hospitalized for HF differed
rom those of non–African Americans in the registry.
frican-American patients tended to be female and younger
nd were more likely to have systolic dysfunction and renal
nsufficiency. Systolic blood pressure (SBP), B-type natri-
retic peptide (BNP), and admission weight were all higher
n hospitalized African Americans. Additionally, the pre-
umed etiology of HF differed significantly between
frican-American and non–African-American patients.
hereas HF etiology in African-American patients was
ore likely to be hypertensive (39.2% vs. 19.3%; p 
.0001), in non–African-American patients it was more
ikely to be ischemic (49.4% vs. 29.5%; p  0.0001).
tiology attributable to other causes (postpartum, valvular,
amilial, alcohol/other drug, chemotherapy, viral, unknown/
diopathic, and other) did not differ between African-
merican and non–African-American patients (31.3% for
ach group). Importantly, 70.5% of the African-American
atients with HF had a nonischemic etiology, either related
o hypertension or causes other than ischemic heart disease.
he mean LVEF was significantly lower in African-
merican patients (35.4% vs. 39.7%; p  0.0001), and the
ercentage of African-American patients with LVSD was
ignificantly higher than that observed in non–African-
merican patients (56.9% vs. 47.1%; p  0.0001).
uality of care. Comparison of the use of process-of-care
easures between racial populations analyzed in this study
emonstrated significant differences. African-American pa-
ients were significantly less likely to receive complete
ischarge instructions and smoking cessation advice, but
hey were more likely to receive LVEF assessment and a
rescription for angiotensin-converting enzyme (ACE) in-
ibitors in the absence of contraindications and intolerance cFig. 1). At discharge, eligible African Americans with
VSD were more likely to be prescribed ACE inhibitors or
ngiotensin receptor blocker drugs (ARBs) (p  0.0001),
ldosterone antagonists (p  0.0001), and hydralazine (p 
.0001) but just as likely as other patients to be prescribed
eta-blocker drugs, warfarin, and nitrates (p  0.225, p 
.118, and p  0.674, respectively) (Fig. 2). African
mericans were less likely to receive statin therapy. Whereas
frican Americans were more likely to be prescribed hy-
ralazine, the percentage of African Americans with LVSD
hat received a combination of hydralazine/isosorbide dini-
rate was only 4.5%. There was documented use of the
rocess-of-care improvement tools in 39.5% of African-
merican patients compared with 46.9% non–African-
merican patients (p  0.0001).
ospital stay and mortality. In unadjusted analyses,
frican-American HF patients experienced a modestly
horter length of stay (5.58 days vs. 5.71 days; p  0.001),
ignificantly lower in-hospital mortality (2.2% vs. 4.1%; p
.0001), and lower follow-up mortality (6.5% vs. 9.1%; p 
.009) (Table 2). However, this patient population had
imilar readmission events (31.7% vs. 29.3%; p  0.12) and
imilar death/repeat hospital stay events (35.3% vs. 36.6%;
 0.44). In multivariable analyses, African-American race
as an independent predictor of lower in-hospital mortality
odds ratio [OR] 0.71, 95% confidence interval [CI] 0.57 to
.87, p  0.001) but was not predictive of follow-up
ortality (hazard ratio 1.12, 95% CI 0.80 to 1.58, p 
.50), follow-up repeat hospital stay (OR 1.14, 95% CI 0.93
o 1.40, p  0.22), or death/repeat hospital stay (OR 1.02,
5% CI 0.86 to 1.22, p  0.79) (Table 2).
A subgroup analysis revealed African-American patients
ith LVSD experienced a shorter length of stay, signifi-
Figure 1 Heart Failure Measures at Hospital Discharge
Percent of patients who received heart failure measures at hospital discharge
by race. ACE  angiotensin-converting enzyme; LVEF  left ventricular ejection
fraction.antly lower in-hospital mortality, and similar follow-up
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nalysis of African-American patients without systolic
ysfunction revealed that this group also had lower in-
ospital mortality but similar length of stay, repeat hospital
tay, and post-discharge mortality compared with that
xperienced by non–African-American patients (Figs. 4A
nd 4B).
ace as an independent predictor of quality of care. Ad-
itional multivariable analyses were performed to assess the
ssociation between African-American race and conformity
ith the American College of Cardiology/American Heart
ssociation (ACC/AHA) performance measures and other
uality indicators for patients hospitalized with HF.
frican-American race was independently associated with
igher ACE inhibitor prescription and left ventricular func-
ion assessment; all other HF quality indicators were not
nfluenced by race (Table 3).
Figure 2 Other Medications at Hospital Discharge
Eligible patients receiving other medications at hospital discharge by race. ACE in
excluding patients with contraindications to ACE inhibitor and/or ARB. †Beta-block
drugs. ‡Statin use in patients with medical history of coronary artery disease, cere
eral vascular disease. §Aldosterone antagonist, hydralazine, and nitrate use in pa
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; HYDR
linical Outcomes for African-American Compared With Non–Africa
Table 2 Clinical Outcomes for African-American Compared With
Hospital Cohort
Unadju
Odds, Hazard, or
Length-of-Stay
Ratio
95% C
In
In-hospital mortality 0.49* 0.4
Length of stay 0.97† 0.9
Follow-up cohort
Post-discharge mortality 0.76‡ 0.5
Repeat hospital stay 1.13* 0.9
Post-discharge mortality/repeat hospital stay 0.96* 0.8Odds ratio. †Length-of-stay ratio. ‡Hazard ratio.iscussion
he OPTIMIZE-HF is a registry-based performance im-
rovement program that enables quality care for patients
ith HF through performance improvement tools and
eedback on patient characteristics, treatments, quality mea-
ures, and clinical events. Our findings from this
PTIMIZE-HF analysis of African Americans with HF
emonstrate that, among participating hospitals, provision
f most but not all quality measures were similar to other
aces. Furthermore, when treated similarly, African-
merican patients have a lower risk-adjusted inpatient
ortality but a similar adjusted 60- to 90-day post-
ischarge morbidity and mortality risk due to HF.
Process-of-care quality-improvement strategies represent
ne potential mechanism for addressing and reversing racial
isparities in cardiovascular care and outcomes (21–23). The
r and/or ARB use in patients with left ventricular systolic dysfunction (LVSD),
in patients with LVSD, excluding patients with contraindications to beta-blocker
ascular accident/transient ischemic attack, diabetes, hyperlipidemia, or periph-
with LVSD. Warfarin use in patients with chronic or paroxysmal atrial fibrillation.
 hydralazine/isosorbide dinitrate.
erican Patients
–African-American Patients
Adjusted
ence
l p Value
Odds, Hazard, or
Length-of-Stay
Ratio
95% Confidence
Interval p Value
9 0.0001 0.71* 0.57–0.87 0.001
9 0.002 0.98† 0.96–1.01 0.193
9 0.041 1.12‡ 0.80–1.58 0.508
2 0.146 1.14* 0.93–1.40 0.215
2 0.591 1.02* 0.86–1.22 0.789hibito
er use
bral v
tients
/ISDNn-Am
Non
sted
onfid
terva
1–0.5
6–0.9
8–0.9
6–1.3
2–1.1
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African Americans Hospitalized With HF: The OPTIMIZE-HF Registry April 29, 2008:1675–84esults of the current study suggest that process-of-care
ntervention programs might benefit African-American as
uch as non–African-American patients, with similar use
f certain evidence-based therapies for HF. Importantly,
ithin the context of a performance-improvement program,
atient race did not influence the quality of HF care
elivered. This is an important observation in light of recent
ndings suggesting that patients with HF or acute myocar-
ial infarction treated at hospitals that disproportionately
reat African-American patients are at high risk for adverse
utcomes and lower quality of care (24,25). Although not
esigned to improve disparate health care, it is plausible that
PTIMIZE-HF or other similar performance improve-
ent programs might represent a unique tool to address
ealth care disparities in HF.
Given a higher cardiovascular risk profile as measured by
everal clinical variables, including a lower mean LVEF,
Figure 3 Outcomes in Patients With Left
Ventricular Systolic Dysfunction
(A) In-hospital outcomes in heart failure patients with left ventricular systolic
dysfunction (LVSD) by race. (B) The 60- to 90-day post-discharge outcomes in
heart failure patients with LVSD by race.igher BNP levels, and greater incidence of renal insuffi-iency, African-American patients in the OPTIMIZE-HF
egistry might have been expected to fare less well. How-
ver, African Americans with HF had lower rates of
n-hospital mortality, regardless of systolic function. Al-
hough this might reflect the younger age of African-
merican patients, these findings persisted after multivari-
ble adjustment, although the OR for in-hospital mortality
oved from 0.49 to 0.71 after adjustment for observed
ovariates. Residual confounding by measured variables and
onfounding by unmeasured variables must still be consid-
red in accounting for these observations. It is also notable
hat African-American patients hospitalized with HF were
n average 11 years younger than non–African-American
atients. This finding underscores the need for increased
F prevention efforts in this population. Uncertain differ-
nces in the pathophysiology of HF in African Americans
emain a potential explanation for these differences in
resentation and are perhaps driven by subtle biological
ifferences including certain genomic variances (26).
Figure 4 Outcomes in Patients Without LVSD
(A) In-hospital outcomes in heart failure patients without left ventricular sys-
tolic dysfunction (LVSD) by race. (B) The 60- to 90-day post-discharge out-
comes in heart failure patients without LVSD by race.
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April 29, 2008:1675–84 African Americans Hospitalized With HF: The OPTIMIZE-HF RegistryPrior studies have shown higher rates of hospital stay in
frican Americans with HF, but the data on mortality rates
ave varied. Analysis of the SOLVD (Studies of Left
entricular Dysfunction) treatment trial suggested that
frican Americans with chronic systolic dysfunction HF
ave increased mortality risk (5). Deswal et al. (27), exam-
ning 4,901 African-American and 17,093 Caucasian Vet-
rans Affairs patients discharged from the hospital for HF,
ound a lower risk-adjusted OR for mortality at 30 days and
years in African Americans with similar readmission rates.
study of 29,372 Medicare beneficiaries hospitalized with
F in 1998 and 1999 also revealed higher repeat hospital
tay rates but lower mortality in African-American patients
ompared with Caucasians (28). Because a substantial propor-
ion of African-American patients hospitalized with HF are
ounger than 65 years of age, Medicare datasets might not be
ufficient to characterize the demographic status, quality of
are, and outcomes for this patient population.
The adequacy of medical therapy is often impugned as an
xplanation for racially disparate outcomes. In the
PTIMIZE-HF registry the differences between African-
merican and non–African-American patients cannot be
xplained by medication prescription, because appropriate
vidence-based therapies were prescribed at similar levels at
he time of hospital discharge. Actual medication compli-
nce, however, might have impacted repeat hospital stays.
frican-American patients were less likely to receive com-
lete discharge instructions and smoking cessation advice at
ischarge. Several studies have shown that pre-discharge
rograms that enhance patient education and consultation
nd conduct follow-up reminders for medical adherence are
ssociated with fewer readmissions and with reductions in
F symptoms (29–31).
The OPTIMIZE-HF performance-improvement pro-
ram was associated with remarkably high ACE inhibitor/
RB and beta-blocker prescription rates at hospital dis-
harge, regardless of race. Notably, African Americans were
ore likely to be prescribed ACE inhibitors and ARBs than
on–African Americans in this registry, and this might have
een responsible in part for better inpatient and short-term
utcomes in African Americans with HF than previously
ndependent Associationf African-American Race and Quality of Care
Table 3 Independent Associationof African-American Race and Quality of Care
Performance Measures and
Other Quality Indicators
Odds
Ratio
95% Confidence
Interval p Value
HF-1: delivery of HF discharge
instructions
1.02 0.94–1.10 0.701
HF-2: left ventricular function
assessment
1.19 1.05–1.34 0.007
HF-3: ACE inhibitor at discharge 1.18 1.01–1.39 0.039
HF-4: smoking cessation
counseling
0.87 0.75–1.02 0.093
ACE inhibitor or ARB at discharge 1.16 0.97–1.39 0.104
Beta-blocker at discharge 0.89 0.71–1.11 0.292
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; HF  heart failure.bserved. In addition to ACE inhibitor usage, clinical trials pnd other registries have shown the importance of beta-
locker use in the African-American population with HF.
n the community-based COHERE (Carvedilol Heart Failure
egistry), carvedilol treatment produced similar results, reduc-
ng hospital stays, HF, and mortality in African-American
nd Caucasian patients (32). The most recent update of
he ACC/AHA clinical practice guidelines for the man-
gement of chronic HF recommends that the African-
merican population receive the same application of
vidence-based therapies as the general population (33).
ur findings would support that statement. The A-HeFT
African-American Heart Failure Trial) study tested isosor-
ide dinitrate/hydralazine as adjunctive therapy for HF in
frican Americans and demonstrated a substantial 43% mor-
ality benefit and a 33% reduction in hospital stays for HF over
ackground therapy with ACE inhibitor/ARB and beta-
locker drugs (6). Despite these substantial benefits, only
.5% of African Americans in the OPTIMIZE-HF registry
ere treated with isosorbide dinitrate/hydralazine. Re-
ent guidelines from the Heart Failure Society of Amer-
ca give the adjunctive use of isosorbide dinitrate/
ydralazine the highest-tier recommendation, with
xpectations that outcomes for African-American patients
ill improve with adherence to guideline-based care (34).
iven the poor adoption of isosorbide dinitrate/hydralazine,
urther opportunities remain to improve care for African-
merican HF patients (6).
tudy limitations. Although the OPTIMIZE-HF registry
epresents an opportunity to study HF patients in a real-
orld setting, there are several limitations to a registry-
ased study that call for careful interpretation of results.
ata were collected by medical chart review and are depen-
ent upon the accuracy and completeness of documentation
nd abstraction. Race was not a self-reported variable but
ather was determined as that documented in the medical
ecord, thus errors in racial determination could have
ccurred. Because of the large number of patients in the
egistry, some small differences that might be of little
linical relevance have p values indicating a high degree of
tatistical significance. These findings might not apply to
ospitals that differ in patient characteristics or care patterns
rom OPTIMIZE-HF hospitals. The 60- to 90-day follow-up
ata are only in a subset of patients in the overall registry and
ight not be representative of the entire aggregate in the
atabase. Medication use was as reported by patients and as
ocumented in the medical record. Actual adherence rates
ight have been lower than reported, and compliance with
edical therapy is not a certainty. Decreased compliance with
edical therapy due to access of care issues affecting the
frican-American cohort might well have been a contributing
actor to the readmission experiences noted in the
PTIMIZE-HF registry. Contraindications and intolerance
ere as documented in the medical record, but a proportion of
atients reported to be eligible for treatment but not treated
ight have had contraindications or intolerance that wereresent but not documented. There were no direct measures of
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ontribution of certain elements affecting similar or disparate
ealth care can only be inferred but not proven with these data.
his study was not a prospective randomized trial, and residual
easured and unmeasured confounders might have influenced
linical outcomes. Prospective randomized studies will be
equired to further test the influence of performance-
mprovement programs on markers of health care disparities.
onclusions
frican-American HF patients, when exposed to a process-of-
are improvement initiative, had better-than-previously ob-
erved treatment with evidence-based therapies. Furthermore,
frican-American HF patients when treated according to
uidelines had similar or better outcomes compared with
on–African-American patients. In adjusted analyses, patient
ace did not influence hospital-based delivery of high-quality
are, as defined by current ACC/AHA HF performance
easures. Further research is required to test the benefit of a
erformance-improvement program on narrowing evidence of
ealth care disparities in African Americans with cardiovascu-
ar disease. In the interim, all appropriate evidence-based
herapies should be employed to improve outcomes in all
atients with HF. The OPTIMIZE-HF program suggests
hat an in-hospital process-of-care improvement program
ight help to achieve similar conformity with quality measures
or African Americans with HF.
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